Etizolam half-life
Controlled healthy-volunteer studies support a short parent-etizolam half-life near 3.5 hours and show that CYP2C19 activity can alter exposure.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Etizolam: evidence and interpretation notes
What the representative value means
Controlled healthy-volunteer studies support a short parent-etizolam half-life near 3.5 hours and show that CYP2C19 activity can alter exposure. The profile treats that enzyme finding as a central source limitation, not a footnote.
The visual model centers on Etizolam at 3.5 hours. Nothing in the calculation adjusts for dose history, organ function, interactions, tolerance, or a study’s sampling method.
Etizolam is a thienodiazepine with direct pharmacokinetic studies, including work showing the importance of CYP metabolism.
The 3.5 hour value makes etizolam a shorter-acting benzodiazepine-like entry in the database. That shorter curve does not by itself describe impairment or dependence risk.
The citations include single- and multiple-dose pharmacokinetic research, CYP2C19-related pharmacokinetic/pharmacodynamic work, and a compound record.
This page is for model interpretation only and does not provide use, tapering, or safety guidance.
For Etizolam, compare the shorter modeled curve with longer benzodiazepine-family entries. The chart can show relative decline, but it cannot show tolerance, rebound, or dependence-related timing.
What each source contributes
- Kato Y et al. Single and multiple dose pharmacokinetics of etizolam in healthy subjects (1991). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
- Sugawara K et al. Pharmacokinetics and pharmacodynamics of etizolam are influenced by CYP2C19 activity (2005). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
- PubChem: Etizolam. This identity record confirms names and compound identity and does not supply a human half-life.
For Etizolam, the numerical model is tied most closely to Kato Y et al. Single and multiple dose pharmacokinetics of etizolam in healthy subjects (1991). As a human pharmacokinetic record, it adds measured route, analyte, and population context; it does not become a universal result.
Why there is no range on the chart
This profile plots 3.5 hours for Etizolam without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 3.5 h as a representative input for Etizolam. In the simplified model, about 0.9% remains after 24 hours and about 3% remains after five half-lives, or roughly 17.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
thienodiazepine context
Thienodiazepine entries sit near benzodiazepine interpretation questions: active metabolites, tolerance, route, repeated use, and residual effects can all complicate one half-life value.
- The curve is not an impairment, withdrawal, or combination-risk guide.
- Source availability can vary by market and product history.
- Compare values only after checking analyte and sampling context.
ComparisonTimeline checkpoints and nearby profiles
Etizolam timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 30.5% | Long-tail portion of the model |
| 12 h | 9.29% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.86% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.01% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Etizolam within the thienodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
No nearby published profiles are available in this category.
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 3.5 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: Controlled healthy-volunteer studies support a short parent-etizolam half-life near 3.5 hours and show that CYP2C19 activity can alter exposure. The profile treats that enzyme finding as a central source limitation, not a footnote.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Research abstract Kato Y et al. Single and multiple dose pharmacokinetics of etizolam in healthy subjects (1991).Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
- Research abstract Sugawara K et al. Pharmacokinetics and pharmacodynamics of etizolam are influenced by CYP2C19 activity (2005).Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
- Identity record PubChem Compound Summary: Etizolam.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the thienodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.